Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de estudo
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mol Carcinog ; 56(7): 1778-1788, 2017 07.
Artigo em Inglês | MEDLINE | ID: mdl-28218462

RESUMO

In the course of our investigations into the toxicity of tungstate, we discovered that cellular exposure resulted in the loss of the histone demethylase protein. We specifically investigated the loss of two histone demethylase dioxygenases, JARID1A and JMJD1A. Both of these proteins were degraded in the presence of tungstate and this resulted in increased global levels of H3K4me3 and H3K9me2, the substrates of JARID1A and JMJD1A, respectively. Treatment with MG132 completely inhibited the loss of the demethylase proteins induced by tungstate treatment, suggesting that tungstate activated the proteasomal degradation of these proteins. The changes in global histone marks and loss of histone demethylase protein persisted for at least 48 h after removing sodium tungstate from the culture. The increase in global histone methylation remained when cells were cultured in methionine-free media, indicating that the increased histone methylation did not depend upon any de novo methylation process, but rather was due to the loss of the demethylase protein. Similar increases of H3K4me3 and H3K9me2 were observed in the livers of the mice that were acutely exposed to tungstate via their drinking water. Taken together, our results indicated that tungstate exposure specifically reduced histone demethylase JARID1A and JMJD1A via proteasomal degradation, leading to increased histone methylation.


Assuntos
Brônquios/enzimologia , Histonas/metabolismo , Histona Desmetilases com o Domínio Jumonji/antagonistas & inibidores , Neoplasias Pulmonares/enzimologia , Metilação/efeitos dos fármacos , Proteína 2 de Ligação ao Retinoblastoma/antagonistas & inibidores , Tungstênio/efeitos adversos , Adenocarcinoma/induzido quimicamente , Adenocarcinoma/enzimologia , Adenocarcinoma/patologia , Animais , Brônquios/citologia , Brônquios/efeitos dos fármacos , Células Cultivadas , Inibidores Enzimáticos/efeitos adversos , Epigênese Genética/efeitos dos fármacos , Histonas/química , Humanos , Histona Desmetilases com o Domínio Jumonji/metabolismo , Neoplasias Pulmonares/induzido quimicamente , Neoplasias Pulmonares/patologia , Masculino , Camundongos , Proteólise/efeitos dos fármacos , Proteína 2 de Ligação ao Retinoblastoma/metabolismo
2.
PLoS One ; 12(3): e0173624, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28306745

RESUMO

Both nickel and cadmium compounds have been established as group I carcinogens for several decades. Despite over-whelming evidence of these compounds' carcinogenicity in humans, the specific underlying molecular mechanisms that govern metal induced cellular transformation remain unclear. In this study, we found that there were slightly different effects on decreased SLBP mRNA and protein as well as increased polyA H3.1 in our nickel exposed cells. This suggested that nickel and arsenic have similar effects on canonical histone mRNA transcription and translation. We also saw that the depletion of SLBP protein was reversed by inhibiting the proteosome. Finally, we showed that inhibiting the SLBP mRNA and protein levels were rescued by epigenetic modifiers suggesting that nickel's effects on SLBP may be mediated via epigenetic mechanisms. Taken together these results suggest a similar mechanism by which both arsenic and nickel may exert their carcinogenic effects.


Assuntos
Cádmio/farmacologia , Níquel/farmacologia , Proteínas Nucleares/genética , Fatores de Poliadenilação e Clivagem de mRNA/genética , Linhagem Celular , Epigênese Genética , Histonas/genética , Histonas/metabolismo , Humanos , RNA Mensageiro/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA